Rona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on the table. #longevity# #RonaTherapeutics# #Roche# #ALK7# #biotech#

$ONDS and $PLTR announced Regna AI, a new company developing specialized AI models for governments and businesses that want to retain control over their models and data. Initially wholly owned by Ondas, Regna will use Palantir’s AI platform and model-training infrastructure. Ondas will also be its first customer. The initial focus is intelligence and surveillance, with models designed to run on drones, ground vehicles and other hardware even with limited connectivity. Initial customer deployments are planned over the coming months.